{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:33:18Z","timestamp":1764239598418},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,1,23]],"date-time":"2010-01-23T00:00:00Z","timestamp":1264204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Community Ment Health J"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10597-009-9288-2","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T11:13:57Z","timestamp":1264158837000},"page":"523-530","source":"Crossref","is-referenced-by-count":19,"title":["Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida\u2019s Medicaid Program"],"prefix":"10.1007","volume":"46","author":[{"given":"Robert J.","family":"Constantine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Andel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,23]]},"reference":[{"issue":"Supplement","key":"9288_CR1","first-page":"1","volume":"161","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association. (2004). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(Supplement), 1\u201356.","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"9288_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.yic.0000224785.68040.43","volume":"21","author":"C Barbui","year":"2006","unstructured":"Barbui, C., Nose, M., Mazzi, M. A., Thornicroft, G., Schene, A., Becker, T., et al. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21(6), 355\u2013362.","journal-title":"International Clinical Psychopharmacology"},{"issue":"6","key":"9288_CR3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004850-200511000-00004","volume":"20","author":"B Biancosino","year":"2005","unstructured":"Biancosino, B., Barbui, C., Marmai, L., Don\u00e1, S., & Grassi, L. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. International Clinical Psychopharmacology, 20(6), 305\u2013309.","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"9288_CR4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11096-006-9063-1","volume":"29","author":"WJ Broekema","year":"2007","unstructured":"Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007). Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharmacy World & Science, 29(3), 126\u2013130.","journal-title":"Pharmacy World & Science"},{"key":"9288_CR5","unstructured":"Center for Medicare Advocacy. (2008). http:\/\/www.medicareadvocacy.org ."},{"issue":"4","key":"9288_CR6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","volume":"161","author":"F Centorrino","year":"2004","unstructured":"Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. American Journal of Psychiatry, 161(4), 700\u2013706.","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"9288_CR7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","volume":"57","author":"MH Chakos","year":"2006","unstructured":"Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., et al. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatric Services, 57(8), 1094\u20131101.","journal-title":"Psychiatric Services"},{"issue":"1","key":"9288_CR8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","volume":"28","author":"RE Clark","year":"2002","unstructured":"Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy. Schizophrenia Bulletin, 28(1), 75\u201384.","journal-title":"Schizophrenia Bulletin"},{"key":"9288_CR9","unstructured":"Clinical practice guidelines. (2005). Treatment of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 50:(13 Suppl 1), 7S\u201357S."},{"issue":"1","key":"9288_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF02629408","volume":"4","author":"RJ Constantine","year":"2006","unstructured":"Constantine, R. J., Richard, S., Surlea, R., et al. (2006). Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis and Therapeutics Reports, 4(1), 5\u201311.","journal-title":"Current Psychosis and Therapeutics Reports"},{"issue":"4","key":"9288_CR11","first-page":"674","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll, C. U. (2008). Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? American Society of Clinical Psychopharmacology, 69(4), 674\u2013675.","journal-title":"American Society of Clinical Psychopharmacology"},{"key":"9288_CR12","unstructured":"Elie, D., Poirier, M., Chianetta, J., Durand, M., Gregoire, C., & Grignon, S. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 1\u20138."},{"issue":"1","key":"9288_CR13","first-page":"26","volume":"5","author":"D Faries","year":"2005","unstructured":"Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry [Electronic Resource], 5(1), 26.","journal-title":"BMC Psychiatry [Electronic Resource]"},{"key":"9288_CR14","unstructured":"Florida Schizophrenia Guidelines. (2005). http:\/\/flmedicaidbh.fmhi.usf.edu\/index.htm ."},{"issue":"5","key":"9288_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","volume":"106","author":"O Freudenreich","year":"2002","unstructured":"Freudenreich, O., & Goff, D. C. (2002). Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(5), 323\u2013330.","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"9288_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.schres.2007.09.002","volume":"98","author":"S Ganesan","year":"2008","unstructured":"Ganesan, S., Taylor, R., Rabheru, K., Forbes, I., Dumontet, J., & Procyshyn, R. M. (2008). Antipsychotic polypharmacy does not increase the risk for side effects. Schizophrenia Research, 98(1), 323\u2013324.","journal-title":"Schizophrenia Research"},{"issue":"10","key":"9288_CR17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","volume":"65","author":"R Ganguly","year":"2004","unstructured":"Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998\u20132000. The Journal of Clinical Psychiatry, 65(10), 1377\u20131388.","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7","key":"9288_CR18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1176\/ps.2007.58.7.1007","volume":"58","author":"TP Gilmer","year":"2007","unstructured":"Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999\u20132004. Psychiatric Services, 58(7), 1007\u20131010.","journal-title":"Psychiatric Services"},{"issue":"2","key":"9288_CR19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1017\/S1461145704004183","volume":"7","author":"DC Goff","year":"2004","unstructured":"Goff, D. C., & Freudenreich, O. (2004). Focus on polypharmacy in schizophrenia: does anyone truly benefit? The International Journal of Neuropsychopharmacology\/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7(2), 109\u2013111.","journal-title":"The International Journal of Neuropsychopharmacology\/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)"},{"issue":"10","key":"9288_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1553-7250(08)34072-0","volume":"34","author":"JL Goren","year":"2008","unstructured":"Goren, J. L., Parks, J. J., Ghinassi, F. A., Milton, C. G., Oldham, J. M., Hernandez, P., et al. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission Journal on Quality and Patient Safety, 34(10), 571\u2013582.","journal-title":"Joint Commission Journal on Quality and Patient Safety"},{"key":"9288_CR21","doi-asserted-by":"crossref","DOI":"10.1201\/9781420035285","volume-title":"Generalized estimating equations","author":"J Hardin","year":"2002","unstructured":"Hardin, J., & Hilbe, J. (2002). Generalized estimating equations. Danvers, MA: CRC Press."},{"key":"9288_CR22","doi-asserted-by":"crossref","unstructured":"Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., Saitoh, O., Iwase, M., Kajimoto, O., Takeda, M., Okabe, S., & Kunugi, H. (2006). Antipsychotic medication and cognitive function in schizophrenia.","DOI":"10.1016\/j.schres.2006.05.004"},{"key":"9288_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.187.3.243","volume":"187","author":"H Ito","year":"2005","unstructured":"Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists\u2019 perceptions of antipsychotic drug prescription. The British Journal of Psychiatry: The Journal of Mental Science, 187, 243\u2013247.","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"issue":"2","key":"9288_CR24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","volume":"188","author":"M Joukamaa","year":"2006","unstructured":"Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122\u2013127.","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"9288_CR25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","volume":"84","author":"J Kreyenbuhl","year":"2006","unstructured":"Kreyenbuhl, J., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research, 84(1), 90\u201399.","journal-title":"Schizophrenia Research"},{"issue":"11","key":"9288_CR26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1192\/pb.26.11.411","volume":"26","author":"P Lelliott","year":"2002","unstructured":"Lelliott, P., Paton, C., Harrington, M., Konsolaki, M., Sensky, T., & Okocha, C. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26(11), 411\u2013414.","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"9288_CR27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","volume":"32","author":"SBTDL Lewis","year":"2006","unstructured":"Lewis, S. B. T. D. L., et al. (2006). Randomized controlled trial of effect of prescription of clozapine verses other second-generation antipsychotic drugs in treatment resistant schizophrenia. Schizophrenis Bulletin, 32(4), 715\u2013723.","journal-title":"Schizophrenis Bulletin"},{"issue":"2","key":"9288_CR28","first-page":"67","volume":"6","author":"DL Loosbrock","year":"2003","unstructured":"Loosbrock, D. L., Zhao, Z., Johnstone, B. M., & Morris, L. S. (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. The Journal of Mental Health Policy and Economics, 6(2), 67\u201375.","journal-title":"The Journal of Mental Health Policy and Economics"},{"issue":"9","key":"9288_CR29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.4088\/JCP.v64n0902","volume":"64","author":"RE McCue","year":"2003","unstructured":"McCue, R. E., Waheed, R., & Urcuyo, L. (2003). Polypharmacy in patients with schizophrenia. The Journal of Clinical Psychiatry, 64(9), 984\u2013989.","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"9288_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19\u201332.","journal-title":"Schizophrenia Research"},{"issue":"1","key":"9288_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a006912","volume":"28","author":"AL Miller","year":"2002","unstructured":"Miller, A. L., & Craig, C. S. (2002). Combination antipsychotics: pros, cons, and questions. Schizophrenia Bulletin, 28(1), 105\u2013109.","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"9288_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clinthera.2007.01.002","volume":"29","author":"EH Morrato","year":"2007","unstructured":"Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a Multistate medicaid population, 1998\u20132003. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, 29(1), 183\u2013195.","journal-title":"Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy"},{"key":"9288_CR33","unstructured":"National Institute for Clinical Excellence. (2002). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care: Clinical Guideline 1."},{"issue":"4","key":"9288_CR34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/070674370104600404","volume":"46","author":"RM Procyshyn","year":"2001","unstructured":"Procyshyn, R. M., Kennedy, N. B., Tse, G., & Thompson, B. (2001). Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. The Canadian Journal of Psychiatry\/La Revue Canadienne De Psychiatrie, 46(4), 334\u2013339.","journal-title":"The Canadian Journal of Psychiatry\/La Revue Canadienne De Psychiatrie"},{"issue":"4","key":"9288_CR35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v64n0402","volume":"64","author":"AJ Rush","year":"2003","unstructured":"Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Trivedi, M. H., et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. The Journal of Clinical Psychiatry, 64(4), 357\u2013369.","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"12","key":"9288_CR36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4088\/JCP.v65n1203","volume":"65","author":"MJ Sernyak","year":"2004","unstructured":"Sernyak, M. J., & Rosenheck, R. (2004). Clinicians\u2019 reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry, 65(12), 1597\u20131600.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"9288_CR37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","volume":"58","author":"K Sim","year":"2004","unstructured":"Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(2), 178\u2013183.","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"9288_CR38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S1461145704004146","volume":"7","author":"SM Stahl","year":"2004","unstructured":"Stahl, S. M. (2004). Focus on Antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology, 7(2), 113\u2013116.","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"9288_CR39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00004850-200311000-00003","volume":"18","author":"T Suzuki","year":"2003","unstructured":"Suzuki, T., Uchida, H., Tanaka, K. F., Tomita, M., Tsunoda, K., Nomura, K., et al. (2003). Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 18(6), 323\u2013329.","journal-title":"International Clinical Psychopharmacology"},{"issue":"6","key":"9288_CR40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hup.959","volume":"23","author":"T Suzuki","year":"2008","unstructured":"Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., et al. (2008). Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology: Clinical and Experimental, 23(6), 455\u2013463.","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"4","key":"9288_CR41","doi-asserted-by":"crossref","first-page":"574a","DOI":"10.1176\/appi.ps.54.4.574-a","volume":"54","author":"A Tapp","year":"2003","unstructured":"Tapp, A. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(4), 574a.","journal-title":"Psychiatric Services"},{"issue":"1","key":"9288_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200831010-00002","volume":"31","author":"C Tranulis","year":"2008","unstructured":"Tranulis, C. (2008). Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety, 31(1), 7\u201320.","journal-title":"Drug Safety"},{"key":"9288_CR43","unstructured":"U.S. Food and Drug Administration: Center for Drug Evaluation and Research. (2007). National drug code directory. http:\/\/www.fda.gov\/cder\/ndc\/database\/default.htm ."},{"issue":"10","key":"9288_CR44","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1185\/030079907X233214","volume":"23","author":"RJ Valuck","year":"2007","unstructured":"Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., & Allen, R. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs. Current Medical Research and Opinion, 23(10), 2567\u20132576.","journal-title":"Current Medical Research and Opinion"},{"key":"9288_CR45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.173.4.325","volume":"173","author":"JL Waddington","year":"1998","unstructured":"Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325\u2013329.","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"9288_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.schbul.a006924","volume":"28","author":"EM Weissman","year":"2002","unstructured":"Weissman, E. M. (2002). Antipsychotic prescribing practices in the veterans healthcare administration\u2013New York metropolitan region. Schizophrenia Bulletin, 28(1), 31\u201342.","journal-title":"Schizophrenia Bulletin"},{"key":"9288_CR47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-244X-8-19","volume":"8","author":"B Zhu","year":"2008","unstructured":"Zhu, B., Ascher-Svanum, H., Faries, D. E., Correll, C. U., & Kane, J. M. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8, 19.","journal-title":"BMC Psychiatry"}],"container-title":["Community Mental Health Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-009-9288-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10597-009-9288-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-009-9288-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:00:34Z","timestamp":1559242834000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10597-009-9288-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,23]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9288"],"URL":"https:\/\/doi.org\/10.1007\/s10597-009-9288-2","relation":{},"ISSN":["0010-3853","1573-2789"],"issn-type":[{"value":"0010-3853","type":"print"},{"value":"1573-2789","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,23]]}}}